HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study.

Abstract
37 patients with disease progression after prior treatment for malignant lymphoma (27 low grade, 7 high grade and 3 Hodgkin's) were treated with oral trofosfamide daily. Most of these patients were heavily pretreated, with a median number of two regimens. Their median performance status was 1 (22 patients with 0-1 and 14 with 2-3). The overall response rate was 49% (18/37; 3/37 CRs and 15/37 (41%) PRs). Median time to progression (TTP) from start of therapy was 4 months for patients with low-grade lymphoma and 2 months for high-grade lymphoma. For responding patients (CR + PR), TTP was approximately 10 and 7 months, respectively, for the two groups of lymphomas. Median survival from the start of treatment was 11 months (range 1.3-46.6) for low-grade lymphoma and 3.8 months (range 2.2-17.6) for high-grade lymphoma. Haematological and other toxicities were low and did not cause any major treatment interruptions. Trofosfamide is an interesting and a non-toxic palliative treatment for relapsing malignant lymphomas especially in elderly patients.
AuthorsM D Helsing
JournalEuropean journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 33 Issue 3 Pg. 500-2 (Mar 1997) ISSN: 0959-8049 [Print] England
PMID9155539 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Cyclophosphamide
  • trofosfamide
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Alkylating (therapeutic use)
  • Cyclophosphamide (analogs & derivatives, therapeutic use)
  • Female
  • Hodgkin Disease (drug therapy)
  • Humans
  • Lymphoma (drug therapy)
  • Lymphoma, Non-Hodgkin (drug therapy)
  • Male
  • Middle Aged
  • Salvage Therapy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: